trending Market Intelligence /marketintelligence/en/news-insights/trending/YlkHF1fW2lRSZk1pmQZAAQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Moody's says Biogen Alzheimer's trial halt is credit negative

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Moody's says Biogen Alzheimer's trial halt is credit negative

Moody's said Biogen Inc.'s discontinuation of clinical trials for the experimental Alzheimer's drug aducanumab is credit negative for the company.

There is no impact on Biogen's Baa1 senior unsecured rating or the stable rating outlook.

The Cambridge, Mass.-based company, together with Japan's Eisai Co. Ltd., stopped two late-stage clinical trials of the investigational Alzheimer's drug after a futility analysis conducted by an independent data monitoring committee showed that the studies were unlikely to meet their main goals.